NCT07059299
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07059299
Title A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma (NeoTISLEGA)
Acronym NeoTISLEGA
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications
Therapies
Age Groups: senior | adult
Covered Countries DEU

Facility Status City State Zip Country Details
Universitätsklinikum Leipzig Leipzig 04103 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field